US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
Patent 11466094 was granted and assigned to Genentech on October, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Chi-Chung Li0
Iraj Hosseini0
Kapil Gadkar0
Saroja Ramanujan0
Yu-Waye Chu0
Edits on 28 Apr, 2023
Golden AI
Infobox
Edits on 12 Oct, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+220 characters)
US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
Article
The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114660940
Date of Patent
October 11, 2022
0Patent Application Number
158136570
Date Filed
November 15, 2017
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11466094 Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
